
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8375271/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer. JCO Oncology Practice, 2022, 18, 319-327.	1.4	40
2	Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172.	12.5	643
3	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	5.1	526
4	IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study Journal of Clinical Oncology, 2022, 40, 470-470.	0.8	6
5	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 862-873.	1.8	568
6	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12.	1.3	43
7	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. Clinical Cancer Research, 2022, 28, 3443-3451.	3.2	19
8	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical Cancer Research, 2022, 28, 2547-2554.	3.2	32
9	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research, 2022, 28, 2297-2305.	3.2	8
10	Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT Journal of Clinical Oncology, 2022, 40, 4078-4078.	0.8	0
11	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Medicine, 2022, 28, 1599-1611.	15.2	185
12	Abstract CT523: An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/β-catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors. Cancer Research, 2022, 82, CT523-CT523.	0.4	1
13	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	3.6	235
14	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607.	1.9	13
15	Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. Targeted Oncology, 2021, 16, 69-76.	1.7	19
16	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2021, 39, 267-267.	0.8	226
17	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist, 2021, 26, e749-e755.	1.9	33
18	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2â^' metastatic breast cancer in US real-world clinical practice. Breast Cancer Research, 2021, 23, 37.	2.2	65

#	Article	IF	CITATIONS
19	Covalent Chemistryâ€Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Advanced Materials Technologies, 2021, 6, 2001056.	3.0	4
20	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology, 2021, 56, 570-580.	2.3	6
21	IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) Journal of Clinical Oncology, 2021, 39. 4071-4071.	0.8	21
22	IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study Journal of Clinical Oncology, 2021, 39, 4073-4073.	0.8	52
23	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. Clinical Cancer Research, 2021, 27, 4848-4858.	3.2	39
24	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 991-1001.	5.1	179
25	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
26	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
27	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 2021, 10, 451-460.	4.2	5
28	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer, 2020, 20, e173-e180.	1.1	21
29	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative metastatic breast cancer. Breast Journal, 2020, 26, 368-375.	0.4	8
30	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-NaÃ ⁻ ve Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 110-121.	3.2	120
31	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 93-104.	4.2	60
32	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202.	0.8	1,255
33	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2020, 73, 1460-1469.	1.8	254
34	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2â^' advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment, 2020, 183, 419-428.	1.1	73
35	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment, 2020, 184, 23-35.	1.1	21
36	Management of ER positive metastatic breast cancer. Seminars in Oncology, 2020, 47, 270-277.	0.8	25

#	Article	IF	CITATIONS
37	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 382, 1894-1905.	13.9	3,828
38	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Research, 2020, 22, 27.	2.2	24
39	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alphaâ€fetoprotein after sorafenib in REACH and REACHâ€2. Liver International, 2020, 40, 2008-2020.	1.9	26
40	Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice. , 2020, , .		13
41	Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2020, 38, 4596-4596.	0.8	7
42	CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Journal of Clinical Oncology, 2020, 38, 483-483.	0.8	17
43	Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC) Journal of Clinical Oncology, 2020, 38, 520-520.	0.8	2
44	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 419-430.	3.0	55
45	The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 51-55.	1.0	4
46	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 282-296.	5.1	1,202
47	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology, 2019, 5, 1-19.	0.5	34
48	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2â^' Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist, 2019, 24, 1514-1525.	1.9	49
49	Progression-free survival: Starting point or endpoint in advanced HCC trial design?. Journal of Hepatology, 2019, 70, 1062-1064.	1.8	7
50	Systemic Therapy for Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 695-715.	0.6	9
51	The Role of Angiogenesis in Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 912-920.	3.2	345
52	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study Journal of Clinical Oncology, 2019, 37, TPS4152-TPS4152.	0.8	94
53	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT) Journal of Clinical Oncology, 2019, 37, 186-186.	0.8	35
54	Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT Journal of Clinical Oncology, 2019, 37, 316-316.	0.8	1

#	Article	IF	CITATIONS
55	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT) Journal of Clinical Oncology, 2019, 37, 317-317.	0.8	26
56	Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma Journal of Clinical Oncology, 2019, 37, 371-371.	0.8	10
57	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68, 723-750.	3.6	3,096
58	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs, 2018, 29, 271-280.	0.7	33
59	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Journal of Hepatology, 2018, 69, 353-358.	1.8	270
60	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, The, 2018, 391, 1163-1173.	6.3	3,542
61	AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018, 67, 358-380.	3.6	2,932
62	Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and metaâ€analysis. Hepatology, 2018, 67, 422-435.	3.6	177
63	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282.	0.8	524
64	Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management. Current Hepatology Reports, 2018, 17, 434-443.	0.4	2
65	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	5.1	1,816
66	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	3.4	124
67	Molecular therapies and precision medicine for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2018, 15, 599-616.	12.5	1,308
68	Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. European Journal of Cancer, 2018, 101, 123-133.	1.3	59
69	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib Journal of Clinical Oncology, 2018, 36, 4003-4003.	0.8	77
70	A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) Journal of Clinical Oncology, 2018, 36, 4076-4076.	0.8	101
71	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma Journal of Clinical Oncology, 2018, 36, TPS4141-TPS4141.	0.8	38
72	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib Journal of Clinical Oncology, 2018, 36, 209-209.	0.8	30

#	Article	IF	CITATIONS
73	Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC) Journal of Clinical Oncology, 2018, 36, 345-345.	0.8	1
74	Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. Journal of Clinical Pharmacology, 2017, 57, 1159-1173.	1.0	30
75	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 56-66.	6.3	2,771
76	Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2017, 35, 4071-4071.	0.8	107
77	Overcoming Treatment Resistance in Hepatocellular Carcinoma: Regorafenib and Lessons from Other Malignancies. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 133-142.	0.1	0
78	Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer, 2016, 5, 221-232.	4.2	44
79	Treating cancer with selective CDK4/6 inhibitors. Nature Reviews Clinical Oncology, 2016, 13, 417-430.	12.5	806
80	Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Research, 2016, 18, 17.	2.2	257
81	Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Cancer Research, 2016, 76, 5822-5831.	0.4	20
82	Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1925-1936.	13.9	1,943
83	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Research, 2016, 18, 67.	2.2	140
84	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	12.5	456
85	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Research and Treatment, 2015, 149, 669-680.	1.1	46
86	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncology, The, 2015, 16, 25-35.	5.1	1,574
87	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research, 2014, 20, 3507-3520.	3.2	100
88	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer, 2014, 3, 439-450.	4.2	21
89	Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology, 2014, 60, 1697-1707.	3.6	279
90	Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research, 2014, 20, 736-743.	3.2	25

#	Article	IF	CITATIONS
91	Survival after sorafenib: Expect the unexpected. Journal of Hepatology, 2014, 60, 243-244.	1.8	8
92	Systemic therapy in HCC: Lessons from brivanib. Journal of Hepatology, 2014, 61, 947-950.	1.8	18
93	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Hepatic Oncology, 2014, 1, 181-188.	4.2	16
94	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1271-1277.	1.8	66
95	A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research, 2013, 19, 6614-6623.	3.2	139
96	AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Research and Treatment, 2013, 141, 397-408.	1.1	21
97	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 2013, 31, 3509-3516.	0.8	544
98	Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatment Reviews, 2013, 39, 219-229.	3.4	120
99	Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines <i>in vitro</i> . Hepatology, 2013, 57, 1838-1846.	3.6	46
100	Emerging Targeted Strategies in Advanced Hepatocellular Carcinoma. Seminars in Liver Disease, 2013, 33, S11-S19.	1.8	58
101	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics, 2013, 12, 890-900.	1.9	67
102	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 270-278.	0.5	59
103	Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab. PLoS ONE, 2013, 8, e56112.	1.1	32
104	Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study Journal of Clinical Oncology, 2013, 31, 300-300.	0.8	5
105	Biologic and Systemic Therapies for the Treatment of Hepatocellular Carcinoma. , 2013, , 363-372.		0
106	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterology and Hepatology, 2013, 9, 1-24.	0.2	5
107	Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib. Molecular Cancer Therapeutics, 2012, 11, 1978-1987.	1.9	68
108	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer, 2012, 1, 247-256.	4.2	65

#	Article	IF	CITATIONS
109	Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2012, 18, 2090-2098.	3.2	167
110	Sorafenib use while waiting for liver transplant: We still need to wait. Journal of Hepatology, 2012, 56, 723-725.	1.8	7
111	HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e55-e60.	0.5	1
112	Brivanib: a review of development. Future Oncology, 2012, 8, 1083-1090.	1.1	25
113	Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study. BMC Cancer, 2012, 12, 16.	1.1	39
114	Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S3783.	0.4	13
115	Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening. Cancer Cell, 2011, 19, 347-358.	7.7	379
116	Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer. Clinical Cancer Research, 2011, 17, 1591-1602.	3.2	247
117	Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2011, 17, 1973-1983.	3.2	142
118	Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clinical Cancer Research, 2011, 17, 6905-6913.	3.2	183
119	Drug therapy: Sorafenib. Hepatology, 2010, 51, 1843-1849.	3.6	23
120	Identification of Common Predictive Markers of <i>In vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines. Molecular Cancer Therapeutics, 2010, 9, 1985-1994.	1.9	59
121	Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?. Clinical Cancer Research, 2010, 16, 390-397.	3.2	98
122	Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244). Cancer Research, 2010, 70, 2264-2273.	0.4	222
123	SRC: A Century of Science Brought to the Clinic. Neoplasia, 2010, 12, 599-607.	2.3	190
124	Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3908-3915.	0.8	154
125	What's positive about â€~triple-negative' breast cancer?. Future Oncology, 2009, 5, 1015-1025.	1.1	22
126	Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study. Journal of Clinical Oncology, 2009, 27, 5552-5558.	0.8	49

#	Article	IF	CITATIONS
127	Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver International, 2009, 29, 284-290.	1.9	53
128	Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Review of Anticancer Therapy, 2009, 9, 503-509.	1.1	96
129	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research, 2009, 11, R77.	2.2	1,131
130	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5544-5552.	0.8	407
131	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative―breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment, 2007, 105, 319-326.	1.1	369
132	Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Research, 2006, 66, 1630-1639.	0.4	846
133	Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology, 2005, 41, 1130-1137.	3.6	333
134	Monoclonal antibody therapy for breast cancer: Herceptin. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 223-233.	0.5	36
135	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 1998, 17, 2235-2249.	2.6	353
136	The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 1997, 15, 537-547.	2.6	317